Exact Sciences Corp. is planning to sell $125 million worth of
shares to the public, according to a statement released by the
Exact Sciences, which is developing a DNA-based, noninvasive
colon cancer test, will use the proceeds from the stock offering
to fund its efforts to obtain FDA approval of Cologuard its
colon cancer test. According to the company, it will also use
the money to fund Cologuard commercialization activities,
product development efforts, and for general corporate purposes.
The offering is subject to market conditions, and there can be
no assurance as to whether or when the offering may be
completed, or as to the actual size or terms of the offering,
according to the statement.
Acting as joint book-running managers for the proposed offering
are Jefferies LLC; Goldman, Sachs & Co.; and Robert W. Baird &